Baicalein has been reported to modulate the CYP3A subfamily and/or P-gp, reversing P-gp-mediated multi-drug resistance in hepatocellular carcinoma (Li et al., 2018) and overcoming P-gp-mediated resistance (Ferreira et al., 2018). This evidence concerns the gene PGP and hepatocellular carcinoma.